ProKidney Corp. (PROK) company profile

ProKidney Corp. is a clinical-stage biotechnology company that develops autologous cell therapies to preserve kidney function in individuals suffering from chronic kidney disease and diabetes. Its lead product candidate, rilparencel, uses selected renal cells harvested from a patient's own kidney biopsy, which are processed and reinjected into the damaged organ through a minimally invasive procedure. Operating in a single segment, the company focuses on creating personalized regenerative treatments that eliminate the need for donor immunosuppression. Its end users are patients with advanced chronic kidney disease and diabetes.

The company maintains its principal executive offices in Winston-Salem, North Carolina, and is incorporated in Delaware following a corporate redomestication from the Cayman Islands. Its operational reach spans clinical research centers located across the United States, Mexico, and Taiwan. Additionally, it operates dedicated internal manufacturing facilities to process patient tissue and produce cell therapies.

Summary of the business section of ProKidney's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, at an initial public offering price per share of $10.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, ProKidney had 231 full-time employees.”